5
November 2024
PureTech Health plc
PureTech Founded
Entity Seaport Therapeutics Names Lauren White as Chief Financial
Officer
Former ImmunoGen CFO will
join Seaport to steer capital financing strategy, accounting,
FP&A and investor relations
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, noted that
its Founded Entity, Seaport
Therapeutics, ("Seaport") a
biopharmaceutical company that is advancing novel neuropsychiatric
medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief
Financial Officer. An accomplished biotech financial executive, Ms.
White most recently served as the Chief Financial Officer at
ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE:
ABBV) for $10.1 billion in 2024.
The full text of the announcement
from Seaport is as follows:
Seaport Therapeutics Names
Lauren White as Chief Financial Officer
Former ImmunoGen CFO will
join Seaport to steer capital financing strategy, accounting,
FP&A and investor relations
BOSTON, November 5, 2024 - Seaport
Therapeutics ("Seaport or the
"Company"), a clinical-stage biopharmaceutical company that is
advancing novel neuropsychiatric medicines with a proven strategy
and team, today announced the appointment of Lauren White as Chief
Financial Officer. An accomplished biotech financial executive, Ms.
White most recently served as the Chief Financial Officer at
ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE:
ABBV) for $10.1 billion in 2024.
"I am so pleased to welcome Lauren
as our CFO as we progress our clinical-stage pipeline of
therapeutics for the treatment of anxiety, depression and other
neuropsychiatric disorders," said Daphne Zohar, Founder and Chief
Executive Officer at Seaport. "Her strong leadership background in
biotech finance will be valuable as we chart an efficient path to
delivering these important new medicines to patients."
Ms. White brings over 22 years of
corporate finance, accounting, strategic partnering and investor
relations expertise to Seaport. As the CFO at ImmunoGen, Ms. White
played a key role on the internal deal team, conducting thorough
analysis and due diligence during the M&A process with multiple
potential buyers, which ultimately led to the successful
acquisition of the company by AbbVie. Additionally, Ms. White
helped to maximize the successful commercial launch of ELAHERE®, a
first-in-class antibody-drug conjugate (ADC) approved for
platinum-resistant ovarian cancer. Before joining ImmunoGen, Ms.
White served as Chief Financial Officer, Treasurer, and Principal
Accounting Officer at C4 Therapeutics (NASDAQ: CCCC), where she was
responsible for developing and leading the company's financial,
capital, and procurement strategies.
Prior to that, Ms.
White held roles of increasing responsibility at Novartis
(NYSE: NVS), most recently serving as Global Head of Financial
Planning and Analysis for the Novartis Institutes for
BioMedical Research (NIBR), where she drove financial strategy
and business planning. Before Novartis, Ms. White held
strategy and marketing roles with Boston Consulting
Group and General Electric. Ms. White received a BS
from the Carroll School of Management at Boston
College and earned an MBA from Harvard Business
School.
"I'm excited to join the outstanding
team at Seaport at this important stage of development," said Ms.
White. "I look forward to working with our team and collaborators
to leverage our recent financial progress and support Seaport's
mission to deliver meaningful medicines that positively impact the
lives of patients and their families."
About Seaport Therapeutics
Seaport Therapeutics is a
clinical-stage biopharmaceutical company advancing the development
of novel neuropsychiatric medicines in areas of high unmet patient
needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are
overcome with its proprietary Glyph technology platform. All
the therapeutic candidates in its pipeline of first and
best-in-class medicines are based on the Glyph platform, which is
uniquely designed to enable oral bioavailability, bypass first-pass
metabolism and reduce liver enzyme elevations or hepatotoxicity and
other side effects. Seaport is led by an experienced team that
invented and advanced important neuropsychiatric medicines and are
guided by an extensive network of renowned scientists, clinicians
and key opinion leaders. For more information, please
visit www.seaporttx.com.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including three that have
been approved by the U.S. Food and Drug Administration. A number of
these programs are being advanced by PureTech or its Founded
Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit
www.puretechhealth.com
or connect with us on X (formerly Twitter)
@puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related to Seaport's
development plans for its pipeline of therapeutics for the
treatment of depression, anxiety and other neuropsychiatric
disorders, potential benefits to patients, and Seaport's and our
future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Justin Chen
+1-609-578-7230
jchen@tenbridgecommunications.com
